{"id":32661,"date":"2017-08-21T10:29:44","date_gmt":"2017-08-21T08:29:44","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=32661"},"modified":"2017-08-22T07:48:31","modified_gmt":"2017-08-22T05:48:31","slug":"chiesi-abbandona-terapia-genica-flop-del-farmaco-piu-caro-della-storia","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/chiesi-abbandona-terapia-genica-flop-del-farmaco-piu-caro-della-storia\/","title":{"rendered":"Chiesi abandons gene therapy. Flop of the most expensive drug in history"},"content":{"rendered":"<p><em>The market did not like the most expensive drug in history, so Chiesi pharmaceuticals decided to abandon the gene therapy sector<\/em><\/p>\n<p>Posted by\u00a0<a title=\"Articles written by: Editorial staff\" href=\"http:\/\/www.parmaquotidiano.info\/author\/redazione\/\" target=\"_blank\" rel=\"author noopener\">Editorial board<\/a>\u00a0hon <a href=\"http:\/\/www.parmaquotidiano.info\/2017\/08\/20\/chiesi-abbandona-terapia-genica-flop-del-farmaco-piu-caro-della-storia\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">20\/08\/2017 \u2013 ParmaQuotidiano.info<\/span><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/www.brindisilibera.it\/wp-content\/uploads\/2017\/04\/Glybera.jpg\" alt=\"Risultati immagini per glybera chiesi\" width=\"385\" height=\"206\" \/>Two years ago, with an investment of 31 million euros, the pharmaceutical industry of Pama had acquired the marketing rights in Italy and in Europe of Glybera, the first drug in the world that uses gene therapy: it modifies the DNA of patients, definitively erasing the defect at the base of these disturbances. An exceptional thing, also in terms of price: one million euros per treatment. (<a href=\"http:\/\/www.parmaquotidiano.info\/2015\/04\/08\/chiesi-vendera-farmaco-da-1-mln-dollari-a-trattamento\/\" target=\"_blank\" rel=\"noopener\">READ HERE<\/a>)<\/p>\n<p>Glybera is used for people with familial lipoprotein lipase deficiency, a rare disease that prevents normal management of ingested fats, causing attacks of pancreatitis. But the results expected from the marketing of the new drug were disappointing, so Chiesi decided to abandon the sector.<\/p>\n<p>Fourteen of the 31 million invested in 2005 were used to support new research for other drugs based on gene therapy, which are being carried out by a Dutch company called Uniqure, which after Glybera is looking for a treatment for haemophilia B, a\u00a0<span class=\"st\">blood clotting disorder.<\/span><\/p>\n<p>In the past weeks, Chiesi has decided not to continue the collaboration with Uniqure: it will no longer bear the enormous research costs for new gene therapies. Glybera had already been withdrawn from the market in recent months: only one treatment had been sold in two years.<\/p>\n<p>Related news: <a href=\"http:\/\/www.fedaiisf.it\/en\/7-farmaci-piu-costosi-del-mondo\/\" target=\"_blank\" rel=\"noopener\">The 7 most expensive drugs in the world<\/a><\/p>\n<p class=\"entry-title\"><a href=\"http:\/\/www.rifday.it\/2017\/04\/26\/malattie-rare-esce-dal-mercato-glybera-farmaco-supercostoso-la-lpdl\/\" target=\"_blank\" rel=\"noopener\">Rare diseases, Glybera, the super expensive drug against Lpdl, goes off the market<\/a><\/p>\n<p class=\"articleTitle\"><a href=\"http:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(15)04537-4\/fulltext?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301515045374%3Fshowall%3Dtrue\" target=\"_blank\" rel=\"noopener\">Cost-Effectiveness Analysis of Glybera for The Treatment of Lipoprotein Lipase Deficiency<\/a><\/p>\n<p class=\"article-header__title\"><a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sctm.16-0487\/abstract;jsessionid=1C276D1C13A41D4CE3CC3D30E30E5327.f03t04\" target=\"_blank\" rel=\"noopener\">Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Il farmaco pi\u00f9 caro della storia non \u00e8 piaciuto al mercato, cos\u00ec Chiesi farmaceutici ha deciso di abbandonare il settore della terapia genica Posted by\u00a0Redazione\u00a0on 20\/08\/2017 &#8211; ParmaQuotidiano.info Due anni fa, con un investimento di 31 milioni di euro, l\u2019industria farmaceutica di Pama aveva acquisito i diritti di commercializzazione in Italia e in Europa di &hellip;<\/p>","protected":false},"author":4,"featured_media":4742,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[29],"class_list":["post-32661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/32661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=32661"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/32661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/4742"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=32661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=32661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=32661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}